Financial Survey: Galmed Pharmaceuticals (GLMD) versus Bioblast Pharma (ORPN)

Galmed Pharmaceuticals (NASDAQ:GLMD) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Galmed Pharmaceuticals and Bioblast Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals 0 0 7 0 3.00
Bioblast Pharma 0 0 0 0 N/A

Galmed Pharmaceuticals currently has a consensus price target of $39.00, suggesting a potential upside of 237.37%. Given Galmed Pharmaceuticals’ higher probable upside, equities analysts plainly believe Galmed Pharmaceuticals is more favorable than Bioblast Pharma.

Earnings & Valuation

This table compares Galmed Pharmaceuticals and Bioblast Pharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galmed Pharmaceuticals $1.09 million 168.73 -$12.29 million ($0.98) -11.80
Bioblast Pharma N/A N/A -$5.94 million N/A N/A

Bioblast Pharma has lower revenue, but higher earnings than Galmed Pharmaceuticals.

Insider & Institutional Ownership

55.8% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 3.1% of Bioblast Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Galmed Pharmaceuticals and Bioblast Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals -1,072.44% -36.66% -33.14%
Bioblast Pharma N/A N/A N/A

Risk and Volatility

Galmed Pharmaceuticals has a beta of 2.64, indicating that its share price is 164% more volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.

Summary

Galmed Pharmaceuticals beats Bioblast Pharma on 5 of the 9 factors compared between the two stocks.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.

About Bioblast Pharma

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply